Convert Pharmaceuticals
PrivateLast Round
Grant
Mar 22, 2023
Total Funding Raised
$19.29M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Convert Pharmaceuticals is a biotechnology company that develops hypoxia-activated prodrugs designed to target and treat solid tumors by exploiting the tumor microenvironment.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Convert Pharmaceuticals Comparables
Compare Convert Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| OncoTherics Limited | 84% | |
| Cascade Prodrug Inc. | 83% | |
| ImmunoGenesis | 72% |
Convert Pharmaceuticals Funding Rounds
Historical fundraising activity
Key People
Founding team and executive leadership
Convert Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Noshaq | Series A |
| Eurostars SME programme | Series A |
| Droia Ventures | Series A |
| Walloon Region (Belgium) | Series A |
| European Innovation Council Fund | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 28, 2026
Monthly visitors increased 220% MoM.
- Mar 22, 2023
$2.7M grant from the European Innovation Council Fund.
Convert Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Convert Pharmaceuticals's valuation, stock price, and market status.
Is Convert Pharmaceuticals a public or private company?
Convert Pharmaceuticals is a private company.
What is the current stock price of Convert Pharmaceuticals?
Convert Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Convert Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Convert Pharmaceuticals worth (valuation)?
Valuation information for Convert Pharmaceuticals is not publicly available.
Can I buy Convert Pharmaceuticals stock?
Convert Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Convert Pharmaceuticals's last funding round?
Convert Pharmaceuticals's most recent funding round was Grant on March 22, 2023.
Who are the main investors in Convert Pharmaceuticals?
Key investors in Convert Pharmaceuticals include Noshaq, Eurostars SME programme, Droia Ventures, Walloon Region (Belgium), European Innovation Council Fund.
Will Convert Pharmaceuticals IPO soon?
No public IPO plans have been announced for Convert Pharmaceuticals.
How can I track Convert Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Convert Pharmaceuticals's shares on secondary markets.